Zytiga

May 29, 2026

Summary The mCRPC market, valued at around USD 8 billion in 2025, is undergoing rapid disruption driven by scientific innovation, patent expirations, and shifting treatment paradigms. Once dominated by blockbuster androgen receptor inhibitors like ZYTIGA and XTANDI, the landscape is now fragmenting under pre...

Jun 06, 2017

Dendreon touts T-cell response data for prostate cancer vaccine Provenge Dendreon has had no shortage of challenges with Provenge since winning FDA approval for the groundbreaking prostate cancer vaccine back in 2010. Years later, the company has unveiled new data showing the med generates a killer T-cell response—a...

Jul 25, 2014

The industry's 10 biggest-selling cancer drugs generated combined sales of $37.4billion in 2013, with Roche's Rituxan, Avastin and Herceptin franchises extending their lead at the top of this league table. With combined sales of around $21 billion, these three drugs alone accounted for approximately 56 percent of t...